A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting now · Phase 2

Conditions studied: Urothelial Carcinoma

In brief

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

Key facts

Study ID

NCT04879329

Run by

Seagen, a wholly owned subsidiary of Pfizer

People needed

372

Starts

2022-05-03

Expected to finish

2029-04-14

Last updated by the study team

2026-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cohorts A and B
• Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra
• Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of platinum-containing chemotherapy
• At least one measurable lesion by investigator assessment based on RECIST version 1.1.
• HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• Cohort C
• Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
• No prior systemic therapy for LA/mUC
• Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy
• At least one measurable lesion by investigator assessment based on RECIST v1.1.
• Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation
• HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample
• ECOG performance status of 0, 1, or 2
• Cohort D
• Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
• Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following lines of therapy for LA/mUC:
• a. One prior line of platinum-containing chemotherapy.
• b. Prior therapy with PD-(L)1 inhibitors as (neo)adjuvant therapy, first-line maintenance therapy or as second line treatment.
• c. Prior enfortumab vedotin therapy.
• At least one measurable lesion by investigator assessment based on RECIST v1.1.
• ECOG performance status of 0 or 1
• Cohort E
• Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
• No prior systemic therapy for LA/mUC

You may not qualify if…

• Cohorts A and B
• Known hypersensitivity to disitamab vedotin or any of their components
• Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohorts A and B)
• Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
• Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy
• Major surgery that has not fully recovered within 4 weeks prior to dose administration
• Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline
• Cohort C
• Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components
• Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study defined as Cycle 1 Day 1 for the single-arm part of Cohort C and as randomization date for the randomized part of Cohort C)
• Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
• Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy
• Major surgery that has not fully recovered within 4 weeks prior to dose administration
• Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
• Participants who have previously received any prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists) are excluded.
• Cohort D
• Known hypersensitivity to disitamab vedotin or any of their components
• Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort D)
• Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
• Prior HER2-directed therapy
• Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy
• Major surgery that has not fully recovered within 4 weeks prior to dose administration
• Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline
• Cohort E

Where it is running

• UCLA Westwood Specialty Care — Los Angeles, California, United States (enrolling)
• Kaiser Permanente Anaheim Kraemer Medical Offices — Anaheim, California, United States (enrolling)
• Foothill Cardioology — Arcadia, California, United States (enrolling)
• Banner Gateway Medical Center — Gilbert, Arizona, United States (enrolling)
• Kaiser Permanente Bellflower Medical Offices — Bellflower, California, United States (enrolling)
• Beverly Hills Multi-Specialties Practice — Beverly Hills, California, United States (enrolling)
• Providence Saint Joseph Medical Center — Burbank, California, United States (enrolling)
• UCLA Burbank Cardiology — Burbank, California, United States (enrolling)
• UCLA Hematology/Oncology - Burbank — Burbank, California, United States (enrolling)
• Banner MD Anderson Cancer Center — Gilbert, Arizona, United States (enrolling)
• UCLA Encino Specialty Care (Radiology) — Encino, California, United States (enrolling)
• UCLA Hematology/Oncoclogy-Encino — Encino, California, United States (enrolling)
• Kaiser Permanente Fontana Medical Center — Fontana, California, United States (enrolling)
• Foothill Cardiology Glendora — Glendora, California, United States (enrolling)
• Kaiser Permanente South Bay Medical center — Harbor City, California, United States (enrolling)
• Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California, United States (enrolling)
• Kaiser Permanente Alton/Sand Canyon Medical Offices — Irvine, California, United States (enrolling)
• UCLA Downtown Los Angeles Primary & Specialty Care — Los Angeles, California, United States (enrolling)
• Kaiser Permanente Los Angeles Medical Offices — Los Angeles, California, United States (enrolling)
• Kaiser Permanente West Los Angeles Medical Center — Los Angeles, California, United States (enrolling)
• Kaiser Permanente Baldwin Park Medical Center — Baldwin Park, California, United States (enrolling)
• Ronald Reagan UCLA Medical Center, Drug Information Center — Los Angeles, California, United States (enrolling)
• UCLA Cardiovascular Center — Los Angeles, California, United States (enrolling)
• UCLA Hematology Oncology — Los Angeles, California, United States (enrolling)
• UCLA Santa Monica Cardiology — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.